1. "Breast Medicine Service"
Formats
  1. Journal Article (2170)
  2. Meeting Abstract (1650)
  3. Review (78)
  4. Book Section (67)
  5. Editorial (42)
  6. Conference Paper (28)
  7. Guidelines (26)
  8. Correspondence (16)
  9. Miscellaneous (11)
  10. Research Letter (10)
  11. Book Whole (5)
Groups
  1. Breast Medicine Service (4103)
  2. Department of Medicine (4103)
  3. Solid Tumor Oncology Division (4103)
  4. Survivorship Research (2337)
  5. GSK Faculty (1492)
  6. Population Sciences Research Program (1339)

More Groups

People
  1. Clifford Hudis (905)
  2. Larry Norton (758)
  3. Mark Robson (676)
  4. Neal Rosen (425)
  5. Andrew Seidman (318)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (57)
  2. 2024 (192)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (802)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (169)
  4. Annals of Oncology (158)
  5. Clinical Cancer Research (128)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (853)
  2. American Association for Cancer Research (749)
  3. Springer (329)
  4. Elsevier Inc. (322)
  5. Oxford University Press (278)
  6. Nature Publishing Group (273)

More Publishers

Results (4103)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Global longitudinal strain in the SAFE-HEaRT study (Cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function)
    Meeting Abstract

    Barac, A.; Lynce, F.; Medvedofsky, D. A.; Geng, X.; Dang, C.; Yu, A.; Tan, M.; Isaacs, C.; Swain, S. M.; Asch, F. M.
    European Heart Journal (2018)

    Fulltext@MSK | Save
  • A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance)
    Meeting Abstract

    Tanioka, M.; Parker, J. S.; Henry, L. N.; Tolaney, S.; Dang, C.; Krop, I. E.; Harris, L.; Hillman, D.; Polley, M.; Berry, D. A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Meeting Abstract

    Yoshino, T.; Iwata, H.; Tamura, K.; Takahashi, S.; Redfern, C.; Modi, S.; Doi, T.; Kawakami, H.; Taniguchi, H.; Takashima, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Tolaney, S. M.; Seidman, A. D.; Anders, C. K.; Ibrahim, N. K.; Rugo, H. S.; Twelves, C. J.; Dieras, V.; Mùˆller, V.; Hannah, A. L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
    Meeting Abstract

    Specht, J.; Pusztai, L.; Forero-Torres, A.; Mita, M.; Weise, A.; Krop, I.; Grosse-Wilde, A.; Wang, Z.; Li, M.; Hengel, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
    Meeting Abstract

    Lacouture, M.; Dion, H.; Ravipaty, S.; Akmaev, V. R.; Sarangarajan, R.; Jimenez, J. J.; Narain, N. R.; Berman, B.; Goldfarb, S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation
    Journal Article

    Wellberg, E. A.; Kabos, P.; Gillen, A. E.; Jacobsen, B. M.; Brechbuhl, H. M.; Johnson, S. J.; Rudolph, M. C.; Edgerton, S. M.; Thor, A. D.; Anderson, S. M.; more...
    JCI Insight (2018)

    Fulltext@MSK | Save
  • First-in-human study of FAZ053, an anti-PD-L1 mAb, alone and in combination with spartalizumab, an anti-PD-1 mAb, in patients with advanced malignancies
    Meeting Abstract

    Janku, F.; Tan, D.; Martin-Liberal, J.; Takahashi, S.; Geva, R.; Gucalp, A.; Chen, X.; Subramanian, K.; Mataraza, J.; Wheler, J.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A counseling framework for moderate-penetrance colorectal cancer susceptibility genes
    Journal Article

    Katona, B. W.; Yurgelun, M. B.; Garber, J. E.; Offit, K.; Domchek, S. M.; Robson, M. E.; Stadler, Z. K.
    Genetics in Medicine (2018)

    Fulltext@MSK | Save